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Abstract: Polymyxins (polymyxin B (PMB) and polymyxin E (colistin)) are cyclic lipodecapeptide
antibiotics, highly basic due to five free amino groups, and rapidly bactericidal against Gram-negative
bacteria, such as the majority of Enterobacteriaceae as well as Acinetobacter baumannii and
Pseudomonas aeruginosa. Their clinical use was abandoned in the 1960s because of nephrotoxicity and
because better-tolerated drugs belonging to other antibiotic classes were introduced. Now, due to the
global dissemination of extremely-drug resistant Gram-negative bacterial strains, polymyxins have
resurged as the last-line drugs against those strains. Novel derivatives that are less toxic and/or more
effective at tolerable doses are currently under preclinical development and their properties have
recently been described in several extensive reviews. Other derivatives lack any direct bactericidal
activity but damage the outermost permeability barrier, the outer membrane, of the target bacteria
and make it more permeable to many other antibiotics. This review describes the properties of three
thus far best-characterized “permeabilizer” derivatives, i.e., the classic permeabilizer polymyxin
B nonapeptide (PMBN), NAB7061, and SPR741/NAB741, a compound that recently successfully
passed the clinical phase 1. Also, a few other permeabilizer compounds are brought up.
Keywords: polymyxin B nonapeptide (PMBN); NAB7061; SPR741/NAB741; Enterobacteriaceae;
Acinetobacter baumannii; Pseudomonas aeruginosa; synergism; permeabilizers; clinical phase 1 study
1. Introduction
Polymyxins (polymyxin B (PMB) and polymyxin E (colistin)) are cyclic lipodecapeptide antibiotics,
highly basic due to five free amino groups, and quite effective against Gram-negative bacteria such
as the majority of Enterobacteriaceae as well as Acinetobacter baumannii and Pseudomonas aeruginosa.
All members of the polymyxin class contain a cyclic heptapeptide core, linked to a linear tripeptide
“panhandle” with an N-terminal fatty acyl moiety (Figure 1). The discovery of polymyxins was
published independently by three laboratories in 1947 [1–3]. In 1948, a Washington D.C. newspaper [4]
wrote “Time will tell, however, whether polymyxin will work in human beings. After all, many of the
wonder drugs have reached this stage only to fail when put to the acid test”.
The clinical use of polymyxins was abandoned in the 1960s because of nephrotoxicity and because
better-tolerated drugs belonging to other antibiotic classes were introduced. Now, due to the global
dissemination of extremely-drug-resistant Gram-negative bacterial strains, polymyxins have resurged
as the last-line drugs against those strains [5–9]. Amongst the alternatives, tigecycline suffers from low
serum and urine levels and ceftazidime-avibactam from the emerging resistance and because it is not
effective against carbapenemases belonging to class B [5,8,9].
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Figure 1. The structure of polymyxin B1 and several compounds structurally related to it. The fatty 
acyl tail of polymyxin B is highlighted with yellow, the linear “panhandle” part (i.e., residues R1-R3) 
with pink, and the cyclic heptapeptide part (i.e., residues R4-R10) with blue. Amino acid residues of 
colistin, PMBN, NAB7061, and NAB741/SPR741 that differ from those in polymyxin B are shown in 
red. 
However, even the new role of polymyxins is now in jeopardy. The recent appearance of mobile 
colistin resistance (mcr) genes has elicited lots of alarms and publicity, but strains resistant to 
polymyxins by other mechanisms, such as those with altered mgrB, display high-level resistance and 
are truly worrisome [10–13]. In the recent SENTRY study (isolates collected worldwide in 2017), the 
frequency of colistin resistance was still very rare; in K. pneumoniae (n = 3,753) only 0.4% and in E. coli 
(n = 7,397) only 0.3% [14]. On the other hand, amongst the global isolates of carbapenemase-
producing K. pneumoniae (n = 1703) and E. coli (n = 407) collected during the SMART program in 2015–
2016, the prevalence of colistin resistance was 21% and 14%, respectively [15]. In 2015, the European 
Antimicrobial Surveillance Network (EARS-Net) registered 33,100 deaths due to infections caused by 
antibiotic-resistant bacteria. Out of these, 6.8% was caused by colistin-resistant E. coli or K. pneumoniae 
and 0.5% by colistin-resistant A. baumannii or P. aeruginosa [16]. 
Polymyxins act specifically on Gram-negative bacteria and are rapidly bactericidal, while Gram-
positive bacteria, eukaryotic microbes and mammalian cells are typically unaffected. They interact 
with anionic lipopolysaccharide (LPS) molecules, exclusively present in Gram-negative bacteria and 
located in the outer leaflet of their outer membrane (OM) [17,18]. The interaction damages the OM. 
The final and lethal action of polymyxins is a damage to the cytoplasmic membrane. As first shown 
by Vaara et al. in 1981, polymyxin-resistance is due to decoration of the lipid A part of LPS by 
phosphorylethanolamine and 4-amino-arabinose, both blocking the anionic binding sites of lipid A 
for polymyxin [19]. 
Polymyxin B and colistin are directly antibacterial. Novel derivatives of them (such as the 
FADDI compounds, CA824, MicuRx compounds, NAB739, and NAB815), all under preclinical 
development, might offer advantages such as enhanced efficacy in experimental infections, as 
recently reviewed by Vaara [20]. Other recent reviews on the development of novel derivatives 
include that of Rabanal and Cajal [21] and that of Brown and Dawson [22]. 
On the other hand, certain derivatives of polymyxins have lost their direct bactericidal activity 
but still damage the OM, restructure it, and weaken its function as a permeability barrier to many 
noxious agents, including antibiotics [17]. Accordingly, they act as “permeabilizers”, “sensitizers”, or 
“potentiators” (i.e., as agents that sensitize the bacteria to other antibiotics or potentiate the action of 
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Polymyxin B2: methyloctanoyl
Colistin A: methylheptanoyl Colistin: R6: L-Leu
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PMBN: absent PMBN: R1: absent
NAB7061: octanoyl NAB7061: R1 absent; R3 aminobutyric acid (Abu)
NAB/SPR741: absent NAB/SPR741: R1 absent; R3 D-Ser
Figure 1. The structure of polymyxin B1 and several compounds structurally related to it. The fatty
acyl tail of polymyxin B is highlighted with yellow, the linear “panhandle” part (i.e., residues R1-R3)
with pink, and the cyclic heptapeptide part (i.e., residues R4-R10) with blue. Amino acid residues
of colistin, PMBN, NAB7061, and NAB741/SPR741 that differ from ose in polymyxin B are sh wn
in red.
However, even the new role of polymyxins is now in jeopardy. The recent appearance of
mobile colistin esistanc (mcr) g nes has elicited lots of alarms and publicity, but strains resistant
to p lymyxins by other mechanisms, such as those with altere mgrB, display high-level resistance
and are truly worrisome [10–13]. In the recent SENTRY study (isolates collected worldwide in 2017),
the frequency of colistin resistance was still very rare; in K. pneumoniae (n = 3753) only 0.4% and in E. coli
(n = 7397) only 0.3% [14]. On the other hand, amongst the global isolates of carbapenemase-producing
K. pneumoniae (n = 1703) and E. coli (n = 407) collected during the SMART program in 2015–2016,
the prevalence of colistin resistance was 21% and 14%, respectively [15]. In 2015, the European
Antimicrobial Surveillance Network (EARS-Net) registered 33,100 deaths due to infections caused by
antibiotic-resistant bacteria. Out of these, 6.8% was caused by colistin-resistant E. coli or K. pneumoniae
and 0.5% by colistin-resistant A. baumannii or P. aeruginosa [16].
Polymyxins act specifically on Gram-negative bacteria and are rapidly bactericidal,
while Gram-positive bacteria, eukaryotic microbes and mammalian cells are typically unaffected.
They interact with anionic lipopolysaccharide (LPS) molecules, exclusively present in Gram-negative
bacteria and located in the outer leaflet of their outer membrane (OM) [17,18]. The inter ction damages
the OM. The final and le hal acti n of polymyxins is a damage t the cytoplasmic membrane. As first
shown by Vaara et al. in 981, pol myxin-resistance is due to decoration of the lipid A part of LPS by
phosphorylethanolamine and 4-amino-ar binose, both blocking the anionic binding sites of lipid A for
polymyxin [19].
Polymyxin B and colistin are directly antibacterial. Novel derivatives of them (such as the FADDI
compounds, CA824, MicuRx compounds, NAB739, and NAB815), all under preclinical development,
might offer advantages such as enhanced efficacy in experimental infections, as recently reviewed by
Vaara [20]. Other recent reviews on the development of novel derivatives include that of Rabanal and
Cajal [21] and that of Brown and Dawson [22].
On the other hand, certain derivatives of polymyxins have lost their direct bactericidal activity
but still damage the OM, restructure it, and weaken its function as a permeability barrier to many
noxious agents, including antibiotics [17]. Accordingly, they act as “permeabilizers”, “sensitizers”,
or “potentiators” (i.e., as agents that sensitize the bacteria to other antibiotics or potentiate the
action of other antibiotics). The directly antibacterial polymyxins also exhibit potentiating activity at
subinhibitory concentrations (see below) but the synergy indices are far lower because of the intrinsic
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activity of the direct-acting polymyxin derivative itself. Quite importantly, it has been shown, in the
case of polymyxin B nonapeptide (PMBN, see below), that the stereochemical configuration is a
determinant of the OM-damaging effect, since the enantiomer of PMBN lacks this activity [23].
This review sums up the properties of polymyxin derivatives that lack any notably direct
antibacterial activity but sensitize the bacteria to other antibiotics.
2. Polymyxin B Nonapeptide (PMBN)
2.1. Synergism
Polymyxin derivatives that lack a fatty acid tail (i.e., des-fatty acyl derivatives) are significantly
less active than polymyxin B against species such as E. coli and K. pneumoniae. On the other hand,
they still possess the OM-permeabilizing activity and, hence, act as permeabilizers that allow enhanced
entry of other antibiotics across the OM [17].
The classic permeabilizer, polymyxin B nonapeptide (PMBN, Figure 1) was discovered by
Vaara and Vaara, published in 1983, and its properties have been extensively reviewed [17].
PMBN lacks the fatty acyl tail as well as the N-terminal diaminobutyryl (Dab) residue and is devoid
of any direct antibacterial activity against enterobacterial species [24,25]. However, even at low
concentrations (1–3 mg/L) it does widen the spectrum of many “anti-Gram-positive” antibiotics
to cover Gram-negative bacteria, as well. These antibiotics include rifampin (decrease in the MIC,
100-fold) as well as erythromycin and fusidic acid (decrease in the MIC, 30-fold) [17]. Target organisms
include E. coli, K. pneumoniae, several other enterobacterial species, and P. aeruginosa.
2.2. Efficacy
The combination of PMBN with erythromycin, as well as with novobiocin, administered
intraperitoneally, protected mice infected with K. pneumoniae or P. aeruginosa in conditions where
none of the agents alone was effective [26].
2.3. Toxicity
PMBN was shown to be 15 times less toxic than polymyxin B in an acute-toxicity assay in mice,
25 times less active in releasing histamine from rat mast cells, approximately 100 times less toxic in
a eukaryotic cytotoxicity assay and approximately 150 times less active in causing neuromuscular
blockade [17]. PMBN elicited no nephrotoxicity in a 23-day dog study and in a 29-day rat study at
doses where polymyxin B did so [27]. Contemporary studies have confirmed the reduced nephrotoxic
potential of PMBN. In vitro, PMBN was >50-fold less cytotoxic than polymyxin B toward human
kidney proximal tubuli cell line HK-2 [28]. Furthermore, polymyxin B1 and colistin preferentially
accumulate in the renal cortical region, while PMBN is more uniformly distributed throughout the
kidney [29]. In a 7-day cynomolgus monkey study, PMBN at the daily dose of 60 mg/kg was less
nephrotoxic than polymyxin B at the daily dose of 12 mg/kg [30].
2.4. Past and Contemporary Use
PMBN has been widely exploited as a useful tool to increase the permeability of the OM in various
in vitro studies, including those dealing with the discovery and development of novel antibacterial
drugs. A selected list of such studies conducted in years before 1992 can be found in the review by
Vaara published in 1992 [17]. Thereafter, at least 16 studies on antibiotic development [31–46] and
more than a dozen studies on bacterial molecular and cellular biology (eight representatives picked up
here [47–54]) have used PMBN as a tool.
3. NAB7061
NAB7061 possesses the same heptapeptide core as polymyxin B, but its side chain consists of
octanoyl-threonyl-aminobutyryl (Figure 1). As a consequence, it carries three positive charges only [55].
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It lacks any notable direct antibacterial activity. However, at 4 µg/mL, it decreased the MIC of rifampin
for E. coli (11 strains), other polymyxin-susceptible Enterobacteriaceae (12 strains), and A. baumannii
(three strains) by factors of 85–750, 10–2,000, and 25–125, respectively [55]. With clarithromycin,
the corresponding decreases in MIC were 90->750, 10–1000, and 40–100-fold, respectively. Furthermore,
NAB7061 decreased the MIC of rifampin and clarithromycin for the polymyxin-resistant K. pneumoniae
strain CL5762B by factors of 24 and 12, respectively [56]. The potentiating activity of NAB7061 has
been verified in vivo in an E. coli peritoneal infection model in mice [57]. In contrast, neither NAB7061
or erythromycin alone was effective. After a single intravenous dose of 1 mg/kg to rats, the urinary
recovery rate for NAB7061 was 7% [58]. When compared to that of colistin sulfate, the renal clearance of
NAB7061 was approximately 30-fold higher. Several other structurally related sensitizing compounds
have been described by Vaara et al., in 2008 [55,59]. NAB7061 has been shown to potentiate the action
of several novel protein translocase SecA inhibitors that are excluded by the intact OM [43].
4. NAB741/SPR741
NAB741, discovered at Northern Antibiotics Ltd. (Espoo, Finland) by Vaara et al. and published
in 2010 [18,60], possesses the same heptapeptide core as polymyxin B, but its side chain consists
of acetyl-threonyl-D-serinyl (Figure 1). Accordingly, and as NAB7061, it carries only three positive
charges, whereas the old polymyxins carry five. Furthermore, it lacks the hydrophobic fatty acyl
tail present in the old polymyxins [18,60]. In 2015, Spero Therapeutics (Cambridge, MA, USA)
in-licensed NAB741 and renamed it as SPR741. Thereafter, SPR741 has been under very extensive
development, as evidenced for instance as the number of posters in the ASM Microbe conferences
(32 posters in 2016–2018). In December 2016, SPR741 entered the clinical phase 1 study. In October
2017, Spero announced that the study yielded positive pharmacokinetic and tolerability data [61].
4.1. Mode of Action
Atomic force microscopy revealed that SPR741 causes undulations (approx. 10 nm) and breaks
(approx. 20 nm) in the OM of E. coli [62]. No substantial impact was found on the cytoplasmic
membrane, as assessed by the method utilizing 3,3′-dipropylthiadicarbocyanine iodine (DISC3(5)) [62].
In contrast to polymyxin B, SPR741 did not release ATP from the cells [63]. Two electron microscopy
studies showed that SPR741 induces the formation of finger-like projections in the OM as well as
blebbing of parts of the OM into medium [64,65]. These effects have previously been shown for
polymyxin and PMBN [17].
4.2. Synergism
As shown by Vaara et al., in 2010 [61], NAB741 is notably synergistic with rifampin and
clarithromycin against E. coli, K. pneumoniae, E. cloacae, and A. baumannii. The potentiation factors
against these bacteria, as defined as the fold reduction in the MIC in the presence of 4 mg/L of SPR741
(relative to the MIC in the absence of SPR741) ranged from >2000 to 16 for rifampin and from 340 to
6 for clarithromycin. Marked synergism was also found with azithromycin, mupirocin, fusidic acid,
and vancomycin against most of these bacterial species [61].
These findings were later corroborated by Corbett et al., in 2017 [66]. Out of 35 antibiotics tested,
the MICs of eight were reduced 32 to 8000-fold against E. coli and K. pneumoniae in the presence of
SPR741. The antibiotics were rifampin, four macrolides/ketolides (clarithromycin, azithromycin,
erythromycin, telithromycin), the pleuromutilin antibiotic retapamulin, fusidic acid, and mupirocin.
Corbett et al. showed that the potentiation factor against E. coli ATCC 25922 in the presence of 8 mg/L
of SPR741 was 8000 for rifampin and 4000 for clarithromycin. Furthermore, SPR741 reduced the
MIC of rifampin, clarithromycin, erythromycin, retapamulin, and fusidic acid for A. baumannii by
>32 fold [66]. Amongst these antibiotics, retapamulin deserves a special interest, since it is a surrogate
of lefamulin [67], an “anti-Gram-positive” antibiotic currently in late clinical development as a drug
administered both intravenously and orally [68].
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Other studies give further support to the original studies by Vaara et al., too. Hackel et al. showed
strong synergism between SPR741 and rifampin, as well as with clarithromycin against recent clinical
isolates of E. coli, K. pneumoniae, and A. baumannii [69]. Mendes et al. showed that SPR741 increases the
activity of rifampin and clarithromycin against Enterobactericeae and A. baumannii, including strains
displaying the MDR phenotype [70]. The potentiation was more marked for SPR741 plus rifampin,
except against the MDR strains of K. pneumoniae. Their subsequent study revealed that the MIC90
values (the MICs for ≥90% of the strains) of clarithromycin in the presence of 8 mg/L of SPR741 were
for E. coli (n = 178), K. pneumoniae (n = 115) and E. cloacae (n = 111), 2, 8, and 1 mg/L, respectively [71].
Both in E. coli and K. pneumoniae, four strains carried acquired resistance elements such as ermB, efflux
pump element mrs, or the macrolide phosphorylase gene mphA [71]. These strains were not susceptible
to the combination of SPR741 and clarithromycin.
In a study exclusively focused on A. baumannii, Zurawski et al. showed that amongst the 29
extensively drug-resistant strains, 28 strains were susceptible to the combination of SPR741 and
rifampin [72]. In the study comprising 100 isolates of A. baumannii, the addition of SPR741 at 8 mg/L
reduced the MIC90 from 16 mg/L to 2 mg/L [73].
Because of the impressive magnitude of potentiation exhibited by rifampin and clarithromycin in
combination with polymyxin derivatives, most of the studies have focused on them as potential partner
antibiotics to SPR741. However, chromosomal resistance to rifampicin, mediated by rpoB, could be
expected to develop as easily in Gram-negative bacteria as has been experienced in Gram-positive
bacteria. Furthermore, many MDR strains of Gram-negative bacteria have already been shown to
possess resistant determinants that confer resistance to macrolide antibiotics (see above). Accordingly,
these two antibiotics may not prove to be the partners of choice in clinical use.
Regarding potential partnering with betalactams, the MDR strains are generally resistant to
piperacillin-tazobactam (TZP), ceftazidime and other betalactams. At the fixed concentration of
8 mg/L, SPR741 decreased the MICs of TZP-susceptible strains of E. coli, K. pneumoniae, and E. cloacae
by a factor of 4–48 and that of TZP-resistant strains by a factor of ≥16 [74]. Quite similar results
were obtained from another laboratory as well as from studies in which SPR741 was combined with
ceftazidime, temocillin, or mecillinam [75–77]. Whether the synergism is due, at least in part, to the
potential SPR741-induced leakage of the periplasmic betalactamases from the bacterial periplasm
into the surrounding medium, has not yet been studied. PMBN is known to release periplasmic
betalactamase as well as other periplasmic proteins into the medium [17]. No synergism was found
between SPR741 and ceftazidime against anaerobic Gram-negative bacteria including Bacteroides spp.,
Fusobacterium spp., Porphyromonas spp., and Prevotella spp. [78].
Amongst the newer drugs under development against Gram-positive bacteria, two groups of
non-quinolone-structured gyrase inhibitors are notably synergistic with SPR741. Both groups inhibit
the gyrB gyrase and the parE topoisomerase IV. The ureabenzimidazole compounds SPR719 and
SPR720 (in-licensed by Spero from Vertex in 2016) as well as the pyridylurea compounds SPR750
and SPR751 (in-licensed by Spero from Biota in 2016) are inactive against Gram-negative bacteria
but in the presence of SPR741 at 8 mg/L their MICs for Enterobacteriaceae and A. baumannii are
notably low (modal MICs, below 1 mg/L) [79–83]. Whether these drugs will be useful partners with
SPR741 in clinical settings, will be seen. Other interesting compounds include the lantibiotic NAI-107,
consisting of 23 amino acyl residues. It has been shown to be very synergistic with polymyxin B
against Enterobacteriaceae and A. baumannii [84].
Other partner candidates will certainly include the tetracycline derivative minocycline. PMBN has
long ago been shown to increase its entry to the cell [85]. However, since the bacteraemic Gram-negative
infections often originate from complicated urinary tract infections (cUTI), it should be noted that
tetracyclines are not very well excreted into urine. Still, other partners may include the streptogramin
combination quinupristin–dalfopristin, as previously shown to be synergistic with NAB7061 [55] and
with SPR741 [66]. Regarding other “old agents”, SPR741 reduces at 8 mg/L the MIC of fosfomycin for
E. coli by a factor of 32 and at 4 mg/L by a factor of 16 [66].
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In screening for any novel drugs under development that might be potential partners for SPR741,
one should note that the desirable pharmaceutical formulation should be intended for intravenous
(IV) use, because SPR741 is administered intravenously. Naturally, if the potential partner is very
well absorbed orally, it might be useful as well. The entire concept of a sensitizer compound and
its partner antibiotic has lots of challenges on its road to become clinically relevant (see Concluding
Remarks below).
4.3. Efficacy in Experimental Infections
In the K. pneumoniae murine model of urinary tract infection, a combination of SPR741 at the
dose of 10 mg/kg every 8 h (thrice a day, TID) and rifampin at the dose of 4 mg/kg TID was
very effective in decreasing the bacterial load in the kidneys, whereas monotherapies with either
agent alone were ineffective [86]. SPR741 at the dose of 10 mg/kg TID subcutaneously plus SPR720
(see above) at the daily dose of 60 mg/L orally was effective in decreasing the kidney bacterial load of
carbapenem-resistant K. pneumoniae while both agents alone lacked any efficacy [87].
In the A. baumannii murine lung model, the combination of SPR741 at 10 mg/kg TID plus
clarithromycin at 100 mg/kg once daily decreased the bacterial load by 1.15 log10 from the
pretreatment [88]. This is remarkable, since the surfactants of the lung alveolar fluid may inactivate
antibiotics as they do inactivate daptomycin. The report also states that SPR741 was effective in the
pneumonia model following infection with E. cloacae expressing blaKPC [88]. In line with these findings,
SPR741 at the dose of 40 mg/kg every 12 h (twice a day, BID) plus rifampin at the dose of 5 mg/kg BID
were therapeutic in an A. baumannii pneumonia model, whereas rifampin alone had only a modest
efficacy [72].
Strains of Enterobacteriaceae seldomly cause complicated skin and soft tissue infections (cSSI).
However, the neutropenic murine thigh infection model (representing cSSI) is widely used in
pharmacokinetic/pharmacodynamic (PK/PD) evaluations. Therefore, five publications describe the
performance of SPR741 in the thigh infection model. The study by Stainton et al., [89] employed
the murine model and strains of Enterobacteriaceae as the challenge organisms and evaluated
the efficacy to be equivalent to human doses (human-simulated regimens [HSR]. They showed
that SPR741 at the HSR dose of 400 mg TIB plus azithromycin at the HSR daily dose of 500 mg
were effective in reducing the bacterial burden, provided that the challenge organism displayed
an azithromycin MIC ≤ 16 mg/L in the absence of SPR741. Accordingly, and quite expectedly,
the combination of SPR741 and azithromycin did not show any effect against most of the strains that
have acquired macrolide-resistance elements such as mphA, mphE, msr, and ermB [89]. The papers by
Warn et al., [88,90,91] show that the combinations of SPR741 with rifampin and with clarithromycin
were highly effective at reducing the thigh burden of mice infected with E. coli, K. pneumoniae and
A. baumannii. Against E. cloacae, the combination of SPR741 and rifampin was effective (clarithomycin
was not tested) [91].
The neutropenic murine thigh infection studies have also included one in which the combined
efficacy of SPR741 and SPR719 (see above) was assessed. Whereas both agents alone were ineffective,
the combination of SPR741 at the daily dose of 180 mg/kg and SPR719 at the daily dose of 150 mg/kg
decreased the bacterial load by approx. 4 log10 from the vehicle control [92]. However, it should be
noted that the doses of both drugs were very high.
4.4. Preclinical Pharmacokinetic and Toxicology Studies
After a single intravenous dose of 1 mg/kg to rats, the urinary recovery rate for NAB741 was
51% [61]. When compared to that of colistin sulfate, the renal clearance of NAB741 was approximately
400 times higher.
The cytotoxicity of SPR741 towards proximal tubular kidney cell lines has previously been shown
to be much lower than that of the old polymyxins [93]. Polymyxin B caused total (>85%) necrosis
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of the electroporated porcine renal proximal tubular LCGPK1 cells at 0.016 mM, whereas a 32-fold
concentration of NAB741 was needed for the same effect [93].
As discussed previously [20], agents that are better-tolerated than the old polymyxins in proximal
tubular kidney cell cultures (i.e., “two-dimensional cultures”) may turn out to be disappointingly
toxic in animal studies. The use of microphysiological systems (MPS) or “organs on chips” that
are three-dimensional organ cultures might be a better predictor [20]. In the MPS utilizing primary
proximal tubular epithelial cells from donors, polymyxin B elicited injury responses such as shedding
of kidney injury molecule-1 (KIM-1) and induction of heme oxygenase-1 (HMOX-1) [94]. At equimolar
concentration, NAB741 had no effect. Furthermore, polymyxin B, but not NAB741, upregulated the
biosynthesis of cholesterol. Finally, NAB741 was bound to cell membranes (POPC lipid nanodiscs)
with an affinity eight-fold lower than that for polymyxin B [94].
A non-GLP 7-day cynomolgus monkey study indicated that SPR741 was at the dose of
60 mg/kg/day less nephrotoxic than polymyxin B at the dose of 12 mg/kg/day [95]. A GLP (good
laboratory practice) study lasting for 14 days indicated that the monkeys tolerated SPR741 at the dose
of 40 mg/kg/day without any adverse effects [96]. The dose of 60 mg/kg/d caused mild to moderate
nephrotoxicity that was fully reversible following a 28-day recovery period [96]. These results are in
line with those obtained with the directly active derivatives NAB739 and NAB815 that carry three
positive charges only. Both were better tolerated in cynomolgus studies than polymyxin B [20].
At the dose of 80 mg/kg/d, the plasma half-life of SPR741 was 1.4 h on day 1 and 2.0 h
on day 14 [97]. SPR741 did not elicit in cynomolgus monkeys any cardiovascular or pulmonary
effects at the single dose of 20 mg/kg. No neurological effects were found in the 14-day GLP study
(80 mg/kg/day) [98]. SPR741 did not inhibit the hERG current at the highest concentration tested
(300 mg/L) [98]. Furthermore, SPR741 was non-genotoxic in the battery of International Conference of
Harmonization (ICH) tests [99]. No cytochrome P-mediated drug–drug interactions were found [100].
4.5. Phase 1 Clinical Trial
In the Phase I clinical trial, SPR741 was well-tolerated as a single intravenous dose of 800 mg
(the highest dose tested) [101]. Subjects receiving SPR741 (maximum dose, 600 mg every 8 h
intravenously, corresponding to the daily dose of 1800 mg) for 14 days tolerated the drug generally
well, too [101]. However, three out of six subjects receiving the maximum dose showed mildly or
moderately decreased clearance of creatinine. The plasma half-life at the dose of 600 mg every 8 h was
approx. 2.3 h on day 1 and approx. 9 h on day 14 [102].
5. Concluding Remarks
Polymyxins increase the permeability of the OM to noxious agents but this action is in most
instances masked by their direct bactericidal action which takes place at the very same concentrations.
However, at subinhibitory concentrations many novel polymyxin derivatives do sensitize the target
to antibiotics, in most studies to the model antibiotic rifampin [103–106]. The direct antibacterial
drug NAB739 has been shown to sensitize at subinhibitory concentrations A. baumannii to rifampin,
clarithromycin, fusidic acid, vancomycin, and meropenem [55].
Furthermore, polymyxin-like novel compounds, such as those under development by
Rabanal et al., may act as sensitizers [107,108]. Sensitizers also include unacylated tridecapeptin
A1 [109] and paenipeptins [110], both having structural relationships with polymyxins.
Linear peptides that carry cationic amino acyl residues integrated to a sequence of hydrophobic
amino acyl residues (such as KFFKFFKFFK; K = lysyl, F = phenylalanyl) act synergistically with
several antibiotics [111]. They may be rather toxic, even though no reports on their tolerability in
animal models have not yet been published. Other permeabilizers that are not structurally related to
polymyxins include those listed by Vaara in 1992 [17] as well as the cationic steroid antibiotics (CSA)
and oligo-acyl-lysyls (OAKs), as reviewed by Zabawa et al., in 2016 [112].
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The “permeabilizer” concept, where a permeabilizer (such as SPR741) makes the OM of the
target bacteria permeable to other agents (partner antibiotics), is scientifically meaningful. Further
studies are needed to evaluate the efficacy and tolerability of the combination of SPR741 with other
antibiotics in clinically relevant conditions. The existence and further development of chromosomal
and acquired resistance against many of the potential partner antibiotics makes the choice of the final
partner very difficult. Furthermore, if both the permeabilizer and the partner completely lack any
direct antibacterial activity by themselves, Phase 2 clinical studies may be quite problematic to justify
in regulatory terms. One of the concrete alternatives for a partner antibiotic to SPR741 in a potential
Phase 2 or Phase 2/3 clinical study would be a wide-spectrum betalactam (piperacillin-tazobactam,
ceftatzidime, aztreonam). They have notable activity even against strains that have been labelled
as nonsusceptible by the laboratory standards. As presented above, SPR41 would potentiate their
action against the target. Whether Spero is going to take SPR741 into the clinical Phase 2 has not
been announced.
Regarding the emerging polymyxin-resistant (PMR) strains (see Introduction), Tascini et al.
showed in 2013 that there is notable synergism with colistin and rifampin against the PMR strains of
Klebsiella pneumoniae that produce carbapenemase [113]. Very recently (2018), two publications have
highlighted the potential of polymyxin-based combinations against PMR strains in a detailed way.
MacNair et al. showed that colistin is notably synergistic in vitro with rifampin, the macrolide antibiotic
clarithromycin, minocycline, and novobiocin against mcr strains [114]. Brennan-Krohn et al. described
the synergism with colistin with rifampin, the macrolide antibiotic azithromycin, minocycline, fusidic
acid, linezolid, and several other drugs against mcr and other PMR strains [115]. Interestingly, also the
novel polymyxin derivative NAB739 [18,20,55] is synergistic with rifampin and retapamulin against
PMR strains [116]. Accordingly, polymyxins that are directly bactericidal against wild-type bacteria
still possess the OM-permeabilizing activity against strains that are resistant to the killing action of
polymyxins. This finding adds new hope in the battle against extremely drug-resistant Gram-negatives.
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